1964
DOI: 10.1097/00000441-196406000-00003
|View full text |Cite
|
Sign up to set email alerts
|

Phenprocoumon, Diphenadione, Warfarin and Bishydroxycoumarin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
6
0

Year Published

1968
1968
2020
2020

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 19 publications
(6 citation statements)
references
References 0 publications
0
6
0
Order By: Relevance
“…During the subsequent six months the investigators observed that the patients who switched to phenprocoumon required about 10% fewer monitoring visits, were substantially more likely to have Thrombotest ® results within the therapeutic range and had significantly lower variance in Thrombotest ® results (13). Other investigators over the past four decades have made similar findings as well (11,(14)(15)(16)(17).…”
Section: Discussionmentioning
confidence: 80%
“…During the subsequent six months the investigators observed that the patients who switched to phenprocoumon required about 10% fewer monitoring visits, were substantially more likely to have Thrombotest ® results within the therapeutic range and had significantly lower variance in Thrombotest ® results (13). Other investigators over the past four decades have made similar findings as well (11,(14)(15)(16)(17).…”
Section: Discussionmentioning
confidence: 80%
“…More than 40 years ago, Rodman et al [18] compared four different anticoagulants, namely warfarin, phenprocoumon, diphenadione and dicoumarol among 126 patients in a randomized, controlled trial. They found that patients treated with phenprocoumon were in therapeutic range 95% of the time compared with 84% in patients treated with warfarin.…”
Section: Discussionmentioning
confidence: 99%
“…They inhibit the production by the liver of the vitamin K‐dependent coagulation factors (factors II, VII, IX and X). A number of studies have suggested that longer‐acting coumarins give a more stable anticoagulation than short‐acting coumarins (Ensor & Peters, 1957; Simson, 1962; Rodman et al , 1964; Sullivan & Kozonis, 1965; Breed et al , 1969; Fekkes et al , 1971; Pattacini et al , 1994), which is thought to be associated with fluctuations in the plasma levels of factor VII induced by the shorter‐acting drugs (Loeliger et al , 1963; Kazmier et al , 1965; Thijssen et al , 1988). Detailed comparisons of different coumarins are rare, which is probably due to the geographical distribution of their use.…”
mentioning
confidence: 99%